SCHEMBL14825535

SCHEMBL14825535

O=C(O)c1ccnc(CN2CCN(C(c3ccccc3)c3ccccc3F)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 2/20 0.53
▸ KDM5C P41229 1/20 0.53
▸ ATM Q13315 3/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ OPRD1 P41143 6/20 0.44
▸ OPRM1 P35372 2/20 0.44
▸ OPRK1 P41145 2/20 0.44
▸ OPRL1 P41146 2/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HDAC1 Q13547 2/20 0.42
▸ KDM4A O75164 1/20 0.42
▸ KDM5A P29375 1/20 0.42
▸ KDM5B Q9UGL1 1/20 0.42
▸ KCNH2 Q12809 3/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825506 0.95 KDM4C (0.56) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825405 0.89 KDM5C (0.62) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825534 0.88 OPRD1 (0.49) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825425 0.88 ATM (0.58) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825519 0.86 KDM4C (0.53) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825843 0.85 KDM5C (0.57) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825365 0.84 KDM4C (0.58) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825844 0.83 KDM5C (0.55) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825493 0.83 KDM4C (0.55) KDM4CKDM5CATMMEN1KMT2A
SCHEMBL14825477 0.82 CACNA2D1 (0.55) KDM4CKDM5CATMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 KDM4C 3070/4885KDM5C 2930/4885ATM 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback